BioAtla (BCAB) Depreciation & Amortization (CF) (2020 - 2026)
BioAtla (BCAB) posted quarterly Depreciation & Amortization (CF) of $120000.0 for Q1 2026, down 34.43% year-over-year from $183000.0 in Q1 2025, and up 531.58% quarter-over-quarter from $19000.0 in Q4 2025.
BioAtla (BCAB) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
BioAtla's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $120000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 34.43% year-over-year to $120000.0; the TTM figure through Mar 2026 stood at $310000.0 (down 64.29% YoY), while the FY2025 annual figure was $373000.0, down 59.68% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $120000.0, up from $19000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $368000.0 in Q4 2023, with the low at $19000.0 in Q4 2025.
- The 5-year median for Depreciation & Amortization (CF) is $240000.0 (2024), against an average of $225764.7.
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) rose 23.49% in 2023, then tumbled 91.67% in 2025.
- BioAtla's Depreciation & Amortization (CF) stood at $298000.0 in 2022, then grew by 23.49% to $368000.0 in 2023, then tumbled by 38.04% to $228000.0 in 2024, then sank by 91.67% to $19000.0 in 2025, then surged by 531.58% to $120000.0 in 2026.
- Business Quant data shows BCAB's Depreciation & Amortization (CF) at $120000.0 in Q1 2026, $19000.0 in Q4 2025, and $56000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 120,000.00 |
| Mar 31, 2026 | 120,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Dec 31, 2024 | 228,000.00 |
| Dec 31, 2024 | 228,000.00 |
| Sep 30, 2024 | 228,000.00 |
| Sep 30, 2024 | 228,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Mar 31, 2024 | 240,000.00 |
| Dec 31, 2023 | 368,000.00 |
| Dec 31, 2023 | 368,000.00 |